A Phase 2b, Dose-Ranging Clinical Study Intended to Optimize Dosage of LLT-BMT1 for Efficacy in the Treatment of Glaucoma and Ocular Hypertension
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs Bimatoprost (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Therapeutic Use
- Acronyms SIGHT-2
- Sponsors MediPrint Ophthalmics
- 06 Feb 2025 Results published in the MediPrint Ophthalmics media release.
- 06 Mar 2024 Results published in the MediPrint Ophthalmics media release.
- 09 Jun 2023 Interim analysis results presented in the MediPrint Ophthalmics Media Release.